ILB® for ALS
Amyotrophic Lateral Sclerosis
Phase 2Active
Key Facts
About TikoMed
TikoMed is a clinical-stage biotech advancing ILB®, a novel therapeutic with a unique mechanism aimed at modulating disease pathology by stimulating endogenous repair processes. The company is actively progressing its lead program in Amyotrophic Lateral Sclerosis (ALS) into clinical studies and has outlined plans for other indications like myocardial infarction. With a seasoned management team and strategic academic partnerships, TikoMed operates as a privately held, pre-revenue entity following a build-and-exit strategy for its asset portfolio.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Cell Therapy for ALS | INCELL | Unknown |
| ALS Research | GliaPharm | Research |
| ALS Disease Model Service | NeuroProof | Pre-clinical |
| ALS Biomarker Program | Linus Biotechnology | Pre-clinical |
| ALS Research (post-RADICAVA) | Tanabe Pharma America | Preclinical/Research |
| ALS Program | Biorchestra | Preclinical |
| Program(s) for ALS | AviadoBio | Pre-clinical |
| TCD601 for ALS | ITB Med | Phase 2 |
| ALS Patient-Led Research Initiative | BGI | Research |
| ALS Pathway Discovery | Anima Biotech | Preclinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |